Abattis signs Andrew Riseman, Ph.D. Associate Professor, Applied Biology and Plant Breeding
VANCOUVER, Jan. 14, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Andrew Riseman Ph.D. effective January 11, 2013. Dr. Riseman will be assisting the Company in Applied Biology and Plant Sciences.
Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are pleased to have Dr. Riseman join our Abattis team. His expertise in tissue and plant breeding sciences will be a tremendous asset to Abattis; we will apply his knowledge to produce proprietary intellectual property for the company. "
Andrew Riseman Ph.D., Associate Professor, Plant Biology and Plant Breeding at UBC stated, I am very excited about this opportunity to work with such a great company to advance botanical sciences in the Medical Marijuana and other medicinal plant breeding sciences, I see Abattis a company with the ability to engineer, grow and extract advanced Pharmaceutical Grade Compounds "PGC's" that ensure traceability, consistency in dosing and safety with a target to produce the purest compounds from chosen cultivars."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and bio-similar
compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and
Animal Nutrition markets. The company also has a deep pipeline of
proprietary products ready for sale in high growth areas of Functional
Foods and Supplements business. For more information, visit the
Company's website at www.abattis.com.
About Dr. Riseman
http://www.landfood.ubc.ca/directory/faculty/professors-and-instructors/andrew-riseman
ON BEHALF OF THE BOARD
| 'Mike Withrow' |
| Michael Withrow, President & CEO |
Neither the CNSX Exchange nor its regulations services accepts
responsibility
for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.
More by this Source
Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
Mar 12, 2013, 15:38 ET
Abattis Terminates $600,000 Private Placement
Mar 11, 2013, 14:31 ET
Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
Mar 08, 2013, 15:53 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.